twenty-six patients ( median age 33 years ) with poor-risk malignancies were treated with high-dose combination chemotherapy associating bcnu-etoposide-cytosine arabinoside and melphalan ( beam ) followed by autologous bone marrow transplantation ( abmt ) .
C0280497
etoposide-cytosine arabinoside
C0015133
beam